Methods

Data and data processing

Deaths

We use country-level age-stratified data on COVID-19 deaths in 19 European countries from 2nd January 2020 to 21st November 2021 from the COVerAGE database (1) – a global demographic database of COVID-19 cases and deaths – which is freely available from the Open Science Framework (2), and from the Institut National d’Études Démographiques (INED) database (3). The COVerAGE data is pre-cleaned and processed to harmonise metrics and age groups (into 10-year intervals up to age 100yrs and then 100-104yrs) across countries (see (2) for details). However, both datasets have periods of missing data and negative counts in the data due to downward corrections of death totals by country health ministries, and the COVerAGE dataset has some errors introduced through the pre-processing. We first clean the data by:

i. Correcting typographical errors that occurred in the entry of the raw data.

ii. Removing values for dates where there is a clear error, e.g. the cumulative death total is lower than for the previous date or a change in the age groups reported in the raw data has led to an error in the age group reaggregation.

We then calculate the cumulative deaths across all ages for each country and merge the dataset with World Health Organization (WHO) country-level data on cumulative deaths, downloaded and cleaned using the covidregionaldata R package (4). We “fill in” periods of missing data at the start of the pandemic and longer periods of missing data (>1 month) in the COVerAGE data for Finland by scaling the cumulative number of deaths in each age group at the end of the period of missing data by the distribution of total deaths over time in the WHO data for that period. We also extrapolate the death time series in recent days/weeks where the age-stratified data for some countries is not fully up-to-date by multiplying the cumulative numbers of deaths in each age group at the most recent time point available by the distribution of total deaths over time since that point in the WHO data. We reaggregate the deaths into the age groups used in the analysis (0-39, 40-49, 50-59, 60-69, 70-79, 80+yrs), and linearly interpolate cumulative deaths for each age group between successive dates where there are
short periods of missing values. Daily numbers of deaths are then calculated by differencing the cumulative death time series.

**Vaccinations**

We use age-stratified data on weekly numbers of vaccinations with different vaccine types in EU countries from 14th December 2020 to 21st November 2021 from the European Centre for Disease Prevention and Control (ECDC) (5) for European Union countries and aggregated age-stratified data on daily numbers of vaccinations with different vaccine types from 8th December to 21st November 2021 for England from the UK government’s COVID-19 dashboard (6). For the ECDC data, we convert weekly numbers of vaccinations into daily numbers of vaccinations by assuming equal numbers of vaccinations occurred on each day of a given week. We categorise the different vaccines into two groups – (A) viral vector and inactivated virus vaccines (AstraZeneca, Janssen, Sputnik and Beijing CNBG), and (B) mRNA vaccines (Pfizer and Moderna) – based on higher effectiveness for mRNA vaccines than viral vector and inactivated virus vaccines but similar effectiveness within these groups, and these being the vaccine types that have been used in European countries. First and second doses of unknown vaccine type are assigned a vaccine type according to the average proportion of each type used for first and second doses for the given age group during that week in other countries. Vaccinations with an unknown age group constitute only 0.008% of all vaccinations (and less than 0.3% of total vaccinations in any one country) so are disregarded. The breakdown of vaccinations by age is missing from the ECDC data for the Netherlands, so we scale the total number of vaccinations by the mean proportion of vaccinations in each age group in each rollout week across countries with age-stratified data (weighted by the relative population proportions of the age groups in each country) to estimate the vaccinations in each age group. Vaccination data for Germany is only available in broader age groups (<18, 19-59, 60+yrs) than we use in the analysis (7). We therefore use data from the Robert Koch Institute’s COVIMO phone survey of vaccine uptake in German citizens (8) (Supplementary Table S2) to estimate the relative coverages in the finer age groups within each of broader age groups, and scale the total numbers of vaccinations over time in the broad age groups by these relative coverages. Whilst this does not fully account for the initial age prioritisation of the vaccine rollout in Germany (Supplementary Figure S1A), it gives more accurate estimates of the current vaccine coverage in the eldest age groups in Germany. We assume fixed delays of 28 days and 14 days for development of protection following first and second doses, corresponding to the time points at which efficacy was measured in clinical trials (Supplementary Table S1).

**Variants**

We use data on frequencies of SARS-CoV-2 variants among sequenced infections in each country from the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV database (9) and The European Surveillance System (TESSy) (10) (collated by the ECDC (11)), and from the COVID-19 Genomics UK (COG-UK) consortium Lineages database (12). We classify variants into three groups – “Other” for pre-existing (pre-Alpha) and other variants, “Alpha”
(B.1.1.7), and “Delta” (all B.1.617.2 variants) – as at the time of writing these are the main variants that have emerged and circulated in European countries.

Vaccine effectiveness

We use estimates of overall vaccine effectiveness against different outcomes – infection ($i$), disease ($d$), hospitalisation ($h$), and death ($m$) – for different doses of different vaccines and different variants from various effectiveness studies to calculate the effectiveness estimates required for our model: those against infection, against disease given infection, against hospitalisation given disease, and against death given disease. We assume that the effectiveness against each outcome of the different vaccines is the same for “Other” variants and the Alpha variant. If $e_i$ is the vaccine effectiveness against infection and $oe_o$ is the overall effectiveness against outcome $o \in \{d, h, m\}$, then we calculate the effectiveness against disease given infection, against hospitalisation given disease, and against death given disease, $e_d$, $e_h$, and $e_m$ respectively, for each dose and variant as:

\[
e_d = \frac{oe_o - e_i}{1 - e_i},
\]
\[
e_h = \frac{oe_o - oe_d}{(1-e_i)(1-e_d)},
\]
\[
e_m = \frac{oe_o - oe_d}{(1-e_i)(1-e_d)}.
\]

Supplementary Table S1 shows the vaccine effectiveness estimates we use in the model and their sources.

Infection fatality risk

For the age-specific SARS-CoV-2 infection fatality risk (IFR) in unvaccinated individuals used in the analysis, we use the ensemble IFR estimate from (13), which combined data on age-stratified COVID-19 deaths up to 1st September 2020 for 45 countries with data from 22 national seroprevalence surveys to estimate the age-specific IFR. COVID-19 deaths were split by long-term care (LTC) residency status in (13) to account for differences in nursing home burdens across countries, so the estimated IFR represents the IFR in non-LTC residents. We incorporate uncertainty in the IFR into our estimates by assuming that the posterior distribution for the IFR for each age group $a$, $IFR_{u,a}$, is approximately truncated normal, with mean equal to the median estimate, $\tilde{IFR}_{u,a}$, standard deviation $\sigma_a$ determined from the lower bound of the 95% credible interval reported in (13), and truncation at 0:

\[
IFR_{u,a} \sim TN(\tilde{IFR}_{u,a}, \sigma_a^2, 0, \infty).
\]
Population age distributions
We use the UN World Population Prospects 2020 population estimates by single-year age from 0-100yrs (14) for the population age distributions of each country. We make the simplifying assumption that population sizes and age distributions have remained constant over the course of the pandemic.

Backcalculation of infections from age-stratified death data
The number of deaths in a particular age group \(a\) on a particular day \(t\), \(D_{a,t}\), is related to the number of infections on preceding days, \(Inf_{a,t-s}\) \((0 \leq s < t)\), by the convolution of the infection counts with the distribution of the infection-to-death delay, \(d_{\text{death}}\), and scaling with the IFR for age group \(a\) on those days, \(IFR_{a,t-s}\), i.e.:

\[
D_{a,t} = \sum_{s=0}^{t} IFR_{a,t-s} Inf_{a,t-s} p_s
\]

where \(p_s = P(d_{\text{death}} = s)\) is the probability of a delay of \(s\) days between infection and death.

For simplicity and consistency of comparisons, and because it is likely to have had the largest influence, we consider only the impact of vaccination on the IFR in this analysis. We model the time-varying IFR as a weighted average of the IFR for unvaccinated individuals and that for vaccinated individuals. Specifically, we want the IFR to reflect the expected split in deaths

Calculation of time-varying infection fatality risk
A number of factors are likely to have affected the SARS-CoV-2 IFR over the course of the pandemic, including surges in demands for hospital beds, improvements in quality of care for hospitalised COVID-19 patients, differences in variant severity, and vaccination. For the sake of simplicity and consistency of comparisons, and because it is likely to have had the largest influence, we consider only the impact of vaccination on the IFR in this analysis. We model the time-varying IFR as a weighted average of the IFR for unvaccinated individuals and that for vaccinated individuals.
between unvaccinated individuals and vaccinated individuals over time based on the effectiveness of the vaccine against infection and against death given infection:

\[
D_{a,t} = \sum_{s=0}^{t} IFR_{a,t-s} \lnf_{a,t-s} p_s = D_{u,a,t} + D_{v,a,t} = \sum_{s=0}^{t} (IFR_{u,a} \lnf_{u,a,t-s} + IFR_{v,a} \lnf_{v,a,t-s}) p_s,
\]

where subscripts \(u\) and \(v\) represent quantities for unvaccinated and vaccinated individuals respectively and \(\lnf_{a,t} = \lnf_{u,a,t} + \lnf_{v,a,t}\), i.e. we want:

\[
IFR_{a,t} = IFR_{u,a} \frac{\lnf_{u,a,t}}{\lnf_{u,a,t}} + IFR_{v,a} \frac{\lnf_{v,a,t}}{\lnf_{u,a,t}} = IFR_{u,a} (1 - \frac{\lnf_{v,a,t}}{\lnf_{u,a,t}}) + IFR_{v,a} \frac{\lnf_{v,a,t}}{\lnf_{u,a,t}}.
\]

Vaccine-induced immunity against hospitalisation and death wanes relatively slowly (19) and reinfections appear to be relatively rare and generally associated with milder symptoms (20), so the proportion of deaths that are from reinfections is likely to be small. This, coupled with the fact that vaccine rollout occurred sufficiently early in most European countries that the number of vaccinated individuals dominates the number of previously infected individuals, and vaccine effectiveness against infection is relatively high, means that the proportion of infections in vaccinated individuals at time \(t\), \(\lnf_{v,a,t}/\lnf_{a,t}\), can be approximated as

\[
\frac{\lnf_{v,a,t}}{\lnf_{u,a,t}} \approx \frac{1 - e_{i,t}}{1 - e_{i,t} c_{a,t}};
\]

where \(e_{i,t}\) is the effectiveness of the vaccine against infection at time \(t\), and \(c_{a,t}\) is the vaccine coverage in age group \(a\) at time \(t\) (21). The IFR for vaccinated individuals is given by:

\[
IFR_{v,a} = P(death|infection, vaccination) = (1 - e_{d,t})(1 - e_{m,t})IFR_{u,a},
\]

where \(e_{d,t}\) is the vaccine effectiveness against disease given infection and \(e_{m,t}\) is the vaccine effectiveness against death given disease. Thus, the time-varying average IFR can be approximated as:

\[
IFR_{a,t} \approx (1 - \frac{(1-e_{i,t}) c_{a,t}}{1 - e_{i,t} c_{a,t}}) + \frac{(1-e_{i,t}) c_{a,t}}{1 - e_{i,t} c_{a,t}} (1 - e_{d,t})(1 - e_{m,t})IFR_{u,a}
\]
The above concise expressions are possible because of the simplifying assumption that immunity does not wane. Including a waning assumption within this IFR calculation would require a less tractable model that tracks the full transmission process, which given available data would likely lead to identifiability issues for many countries.

We model all vaccinations together and account for differences in the vaccine effectiveness against different outcomes between different vaccine types and doses and virus variants by treating the effectiveness as time dependent and averaging it over the relative proportions of the different vaccine types and doses and circulating variants in each country over time. I.e., if \( e_{o,t} \) is the protection against outcome \( o \in \{i, d, m\} \) at time \( t \), then:

\[
e_{o,t} = \sum_v \sum_j p_{v,j,t} \sum_k p_{k,t} e_{o,v,j,k}
\]

where \( p_{v,j,t} \) is the proportion of vaccinees who have been vaccinated with dose \( j \) of vaccine \( v \) by time \( t \), \( p_{k,t} \) is the relative proportion of variant \( k \) circulating at time \( t \), and \( e_{o,v,j,k} \) is the protection from dose \( j \) of vaccine \( v \) against outcome \( o \) from infection/disease with variant \( k \). Currently, we only consider numbers of first and second doses \( (j \in \{1, 2\}) \) of each vaccine, i.e. we do not include booster doses. The relative proportions of the different variants over time are estimated as described below.

**Estimation of variant proportions over time**

We estimate the relative proportions of the “Other”, Alpha, and Delta variants over time in each country by fitting multinomial regression models to the frequencies of sequenced variants of each type in GISAID data and COG-UK data, in line with several other studies (18,22,23). We test two fixed-effect multinomial models: one with just sample date as the explanatory variable and one with a two-degrees-of-freedom natural cubic spline function of sample date as the explanatory variable (18). The models are fitted using the `multinom` function in the `nnet` R package and their fit is compared using Akaike Information Criterion (AIC). The model with the lowest AIC, the cubic spline model, is selected and used to calculate the variant proportions over time for each country. The input data and estimated variant proportions over time are shown in Supplementary Figure S7.

**Deconvolution of deaths to infections**

Having calculated the time-varying IFR, we estimate the time series of infections for each age group for each country using the Robust Incidence Deconvolution Estimator (RIDE) provided in the `incidental` R package (24,25), an empirical Bayes deconvolution algorithm developed and validated for inferring SARS-CoV-2 infection time series from case/hospitalisation/death time series (18,24). RIDE uses a cubic spline model for underlying infections and a Poisson likelihood to describe observed cases/deaths. The degrees of freedom of the spline basis are chosen based on lowest AIC over a grid of pre-specified values, and a regularisation penalty is
imposed on the second difference of the spline parameters to encourage smoothness, and the regularisation parameter chosen by maximising held-out log-likelihood from splitting of the data into training and validation data sets over a grid of pre-set values (see (24,25) for further details). We use a grid of the even numbers between 6 and 30 for the degrees of freedom of the cubic spline – a wider range than the default setting (6 to 20) to allow sufficient flexibility to fit the observed death time series. RIDE handles right censoring of the death time series by making multiple extrapolations of the observed death curve with a simple autoregressive random walk model that has the same autocorrelation as the observed data. The mean of the autoregressive model is determined by fitting a linear model to the tail of the observed death curve over a certain time window. We use a longer time window (28 days vs 14 days) and higher prior precision (100 vs 10) for the slope of the extrapolation than the default values in order that the inferred infection curve reflects the considerable uncertainty in the future epidemic trajectory.

We first aggregate COVID-19 deaths into the following age groups: 0-39, 40-49, 50-59, 60-69, 70-79, 80+yrs. The age grouping is chosen to ensure that there are sufficient deaths in the youngest age group to reliably infer the underlying infection time series even for countries with low numbers of deaths, since the IFR increases approximately exponentially with age (13,26) and low numbers of deaths lead to unstable estimates of infections (24,27).

We then split deaths by LTC residency status as there is substantial evidence that IFRs among LTC residents have been higher than in the same age groups outside of LTC facilities (13,28–30). We assume that all deaths in LTC facilities occurred in individuals aged 60yrs and older, and use data on the proportion of all deaths that have occurred in care homes, \( p_{LTC} \), for each country from the LTCcovid platform (13,28) to estimate the proportion of deaths amongst those aged 60yrs and over that have occurred in care homes. Namely, if \( p_{60+} \) is the proportion of all deaths amongst individuals 60+yrs, we calculate the number of deaths amongst those 60+yrs that occur among LTC residents in each age group \( a \), \( D_{a,t,LTC} \) as:

\[
D_{a,t,LTC} = \frac{p_{LTC}}{p_{60+}} D_{a,t}, \quad a \geq 60\text{yrs},
\]

and the number of non-LTC deaths amongst individuals 60+yrs, \( D_{a,t,nLTC} \) as:

\[
D_{a,t,nLTC} = D_{a,t} - D_{a,t,LTC}, \quad a \geq 60\text{yrs}.
\]

For France the reported death data is for hospital deaths only, so we estimate the proportion of deaths among those 60+yrs as:

\[
p_{60+} = p_{LTC} + (1 - p_{LTC}) \frac{\sum_a \sum_t D_{a,t,Hosp}}{\sum_a \sum_t D_{a,t,Hosp}}
\]

and scale up the hospital deaths among those 60+yrs to obtain overall deaths in those 60+yrs:
\[ D_{a,t} = \frac{D_{a,t,\text{hosp}}}{1 - \frac{p_{\text{hosp}}}{p_{a,t}}}, \quad a \geq 60\text{yrs}. \]

For countries for which information on the proportion of deaths among LTC residents is not available, we use the mean proportion across countries for which LTC death data is available.

With deaths split in this way, we run RIDE on the time series of deaths for each age group under 60yrs and the separate time series for non-LTC and LTC residents for each age group over 60yrs to estimate the time series of infections that led to these deaths. We then calculate the overall number of infections by dividing by a value of the IFR for the corresponding age group drawn from the distribution in Equation (1). Following (13), we take the relative frailty factor for death from COVID-19 for LTC residents to be \( \gamma = 3.8 \), i.e. use a 3.8 times higher IFR for LTC residents than non-LTC residents.

From the deconvolution of the death time series, RIDE produces a maximum a posteriori estimate and 1000 posterior samples of the underlying infection time series, which we use to calculate 95% credible intervals (CIs) (as the 2.5th-97.5th percentile interval) for the number of individuals that have been infected and the remaining burden of hospitalisations and deaths.

**Calculation of proportions in different immune states**

We estimate the numbers of individuals in different infection states (susceptible, vaccinated, recovered, etc.) in each age group \( a \) over time \( t \) from the inferred numbers of infections \( \text{Inf}_{a,t} \) (for non-LTC residents and LTC residents) using the following discrete-time difference equation model (18)

\[
\begin{align*}
S_{a,t+1} &= S_{a,t} - nSE_{a,t} - nSV_{a,t} \\
V_{a,t+1} &= V_{a,t} + nSV_{a,t} - nVE_{a,t} - nVL_{a,t} \\
E_{a,t+1} &= E_{a,t} + nSE_{a,t} + nVE_{a,t} - nEL_{P,a,t} - nEL_{S,a,t} \\
L_{a,t+1} &= L_{a,t} + nVL_{a,t} - nLI_{S,a,t} \\
I_{S,a,t+1} &= I_{S,a,t} + nEI_{S,a,t} + nLI_{S,a,t} - nIR_{S,a,t} \\
I_{P,a,t+1} &= I_{P,a,t} + nEI_{P,a,t} - nIR_{P,c,a,t} \\
I_{C,a,t+1} &= I_{C,a,t} + nIR_{P,c,a,t} - nIR_{C,a,t} \\
R_{a,t+1} &= R_{a,t} + nIR_{S,a,t} + nIR_{C,a,t} \\
nSE_{a,t} &= \frac{S_{a,t}}{S_{a,t} + (q + r)V_{a,t}} \cdot \text{Inf}_{a,t} \\
nVE_{a,t} &= \frac{qV_{a,t}}{S_{a,t} + (q + r)V_{a,t}} \cdot \text{Inf}_{a,t}
\end{align*}
\]
The maximum remaining hospitalisations \( H_{\text{rem},a} \) and deaths \( D_{\text{rem},a} \) in each age group in each country (assuming no emergence of immune escape variants) are calculated from \( S_{a,T} \), \( V_{a,T} \), and

\[ nVL_{a,t} = \frac{rV_{a,t}}{s_{a} + (q + r)V_{a,t}} \ln f_{a,t} \]
\[ nEI_{p,a,t} = \gamma_a nEI_{a,t} \]
\[ nEI_{S,a,t} = (1 - \gamma_a) nEI_{a,t} \]
\[ S_{a,0} = N_a, V_{a,0} = 0, E_{a,0} = 0, L_{a,0} = 0, \]
\[ I_{S,a,0} = 0, I_{P,a,0} = 0, I_{C,a,0} = 0, R_{a,0} = 0. \]

Here \( X_{a,t} \) is the number of individuals in state \( X \) (one of: \( S \) susceptible, \( V \) vaccinated, \( E \) latently infected, \( L \) latently infected following vaccination but protected from clinical infection, \( I_S \) subclinical infection, \( I_P \) preclinical infection, \( I_C \) clinical infection, \( R \) recovered) in age group \( a \) at time \( t \); \( nXY_{a,t} \) is the number of individuals who move from state \( X \) to state \( Y \) in age group \( a \) at time \( t \); \( q_t = (1 - e_{a,t})(1 - e_{d,t}) \) and \( r_t = (1 - e_{i,t})e_{d,t} \) capture the average vaccine protection against disease and infection at time \( t \); \( nEI_{a,t} \) is the total number of individuals leaving the preclinical infection state in age group \( a \) at time \( t \); \( \gamma_a \) is the age-dependent clinical fraction (31); and \( N_a \) is the population of age group \( a \). The numbers of individuals moving between different infection states – \( nEI_{p,a,t}, nEI_{S,a,t}, nLI_{S,a,t}, nLI_{P,a,t}, nLI_{C,a,t}, nLI_{R,a,t} \) – are determined by the waiting time distributions \( (d_E, d_L, d_P, d_C, d_S) \) for each of the infection states \( (E, L, I_P, I_C, I_S) \), which are given in Supplementary Table S3.

To account for the fact that not all vaccinations are administered to susceptible individuals, we model the number of vaccinations given to susceptible individuals at time \( t \), \( nSV_{a,t} \), as the total number of vaccinations \( nV_{a,t} \) multiplied by the proportion of those still to be vaccinated coming from the susceptible state, i.e.:

\[ nSV_{a,t} = \min\left(\frac{s_{a,t}}{(1 - e_{a,t})N_a} nV_{a,t}, S_{a,t}\right) \]

where the minimum function is to ensure the number of susceptible individuals cannot become negative. Solving the difference equations allows us to estimate how many susceptible (unexposed and unvaccinated) individuals \( S_{a,T} \), uninfected vaccinees \( V_{a,T} \), and previously infected individuals \( R_{a,T} \) there are currently (at time \( t = T \)) in each age group in each country.

**Calculation of remaining burden**

The maximum remaining hospitalisations \( H_{\text{rem},a} \) and deaths \( D_{\text{rem},a} \) in each age group in each country (assuming no emergence of immune escape variants) are calculated from \( S_{a,T} \), \( V_{a,T} \), and
assuming that all individuals in the population are exposed now (i.e. no further vaccinations occur) and that previous infection confers a similar degree of protection against subsequent infection, hospitalisation and death as vaccination with two doses of a type A vaccine or two doses of a type B vaccine (we use the variant-proportion-weighted average of the values in Supplementary Table 1) (32). Thus all susceptible individuals become infected and a proportion of uninfected vaccinees and previously infected individuals become infected that depends on the protection against infection afforded by vaccination/previous infection. We assume that the proportion of infections in each age group ≥60yrs that occur in LTC facilities, \( p_{\text{Inf,a,LTC}} \), remains the same as it is now (as estimated from the deconvolution), and assume that the relative frailty factor for hospitalisation from COVID-19 for LTC residents is the same as that for death from COVID-19. So, using estimates of the infection hospitalisation risk \( IHR_{u,a} \) (33) and infection fatality risk \( IFR_{u,a} \) (13) in unvaccinated individuals from the literature, \( H_{\text{rem,a}} \) and \( D_{\text{rem,a}} \) are given by:

\[
H_{\text{rem,a}} = H_{\text{rem,a,S}} + H_{\text{rem,a,V}} + H_{\text{rem,a,R}}
\]

\[
= (1 - p_{\text{Inf,a,LTC}} + p_{\text{Inf,a,LTC}} e^{\gamma}) (IHR_{u,a} S_{a,T} + (1 - e_{i,T}^{\gamma}) IHR_{u,a} V_{a,T} + (1 - e_{i,T}^{\gamma}) IHR_{u,a} R_{a,T})
\]

\[
= (1 - p_{\text{Inf,a,LTC}} + p_{\text{Inf,a,LTC}} e^{\gamma}) (IFR_{u,a} S_{a,T} + (1 - e_{i,T}^{\gamma}) IFR_{u,a} V_{a,T} + (1 - e_{i,T}^{\gamma}) IFR_{u,a} R_{a,T})
\]

where

\[
e_{o,T}^{\gamma} = \frac{1}{2} \sum_{v,k} p_{k,T} e_{o,v,2k}
\]

is the average of the type A and type B two-dose vaccine effectiveness \( e_{o,v,2k} \) against outcome \( o \in \{i, d, h, m\} \) weighted according to the proportions of the currently circulating variants \( p_{k,T} \). We incorporate uncertainty in the estimated IHR in unvaccinated individuals from (33) by assuming that the posterior distribution for the IHR in each age group \( a \), \( IHR_{u,a}^{\gamma} \) is approximately truncated normal, with mean equal to the median estimate, \( IHR_{u,a}^{\gamma} \) standard deviation \( \sigma_{H,a} \) determined from the lower bound of the 95% credible interval reported in (33), and truncation at 0:

\[
IHR_{u,a}^{\gamma} \sim TN(IHR_{u,a}^{\gamma}, \sigma_{H,a}^2, 0, \infty).
\]

We calculate 95% CIs for the remaining hospitalisations and deaths by repeating the above calculations for each of the 1000 posterior samples of the infection time series generated by the
deconvolution and IFR scaling (each time with a separate draw for the IHR and the draw for the IFR used in the backcalculation), and calculating the 2.5th-97.5th percentile of the resulting distribution.

Comparison of inferred infections with reported cases

For comparing the inferred infection time series with time series of reported cases, we convolve the inferred infection time series with the incubation period (time from infection to symptom onset), which we take to be the convolution of the latent period \( \tau \sim \text{Gamma}(2.5, 1) \) and the preclinical infectious period \( d_p \sim \text{Gamma}(4, 0.625) \), which gives a distribution with mean 5 days and standard deviation 2 days (18). Supplementary Figure S8 shows that the temporal patterns of inferred infections and reported cases match closely across virtually all countries and age groups. Inferred infections are higher than reported cases for all but a few age groups in a few countries, with larger differences for younger age groups. This is as expected given under-reporting of symptomatic infections, the high proportion of asymptomatic infections, and the decrease in the asymptomatic proportion with increasing age (31).

Limitations

The main limitations of our analysis are that it only provides a theoretical upper bound on the potential number of hospitalisations and deaths that could occur in the different countries considered, and that it does not account for waning of immunity, the rollout of boosters or the emergence of new variants. Our approach is also reliant on a number of relatively strong assumptions. Firstly we assume that COVID-19 deaths are completely and sufficiently consistently reported across different countries such that they can be used to estimate and compare cumulative infection burden between countries. However, even among European countries, where reporting of COVID-19 deaths is likely to be more complete than elsewhere, it is possible that there is some under-reporting of COVID-19 deaths, and definitions for COVID-19 deaths differ to some extent between countries and in some countries have changed over time (34). Potential differences in reporting of COVID-19 deaths could be further explored by examining the ratio of excess deaths to COVID-19 deaths reported in each country over time (35).

We also assume that the delay between infection and reported date of death and the age-dependent IFR in unvaccinated individuals are similar enough across countries that we can use the same values for all countries when inferring underlying infections. Different countries use different types of date (occurrence, registration, report) to report deaths so there is likely some variation in the delay between infection and reported death date (34) and there may also be some variation in the delay between infection and occurrence of death between countries due to differences in availability and quality of ICU care. There is also evidence of additional variation in the IFR between countries over that expected just from differences in population age structure (13). However, we believe that the variation in these quantities for the countries considered is likely to be sufficiently small (see Figure 2C in (13) for variation in the
population-weighted IFR for the countries we analyse) that it would not significantly change our estimates.

We only consider variation in the IFR due to vaccination, but there are several other potential sources of variation, including differences in severity between variants. Several studies have reported progressively increased severity (corresponding to a higher IFR and/or IHR) for Alpha and Delta in unvaccinated individuals over the original virus strain (36–40), but have not found statistically significant differences in relative risks of hospitalisation and death between variants for vaccinated and unvaccinated individuals (38,39). The severity of different variants may therefore differ less for vaccinated individuals than unvaccinated individuals. Furthermore, comparison of our estimates for the cumulative proportion infected or vaccinated in England with age-stratified seroprevalence estimates suggests that our approach captures the overall change in the IFR that has occurred over time relatively accurately (Supplementary Figure S3).

The approximation of the split of infections between unexposed & unvaccinated individuals and vaccinated individuals that we use to construct the time-varying IFR (Equation (3)) assumes that vaccination rollout happened early and fast enough in most countries that the vaccinated proportion of the population dominates the proportion previously infected. It also assumes that vaccine effectiveness against infection is relatively high so the number of breakthrough infections is small relative to the number of infections in unvaccinated individuals, and the current number of vaccinated individuals can be roughly approximated by the vaccination coverage. Whilst these assumptions are reasonable for most of the European countries we consider and for the time period we analyse, they are less valid for other countries where vaccine rollout has been slower, which limits the potential applicability of the analysis beyond the countries considered. The deconvolution method also does not account for reinfections, but to date the proportion of infections that are reinfections appears to be relatively small and protection against severe outcomes from previous infection (20) likely means that the contribution of reinfections to deaths is small.

Another limitation of our analysis is that the deconvolution method relies on sufficient numbers of deaths in each age group to produce stable and temporally accurate estimates of infections. Combined with the approximately exponential increase in the IFR with age, this means that we have to use a large lowest age group (0-39yrs) to obtain reliable infection estimates for countries with low numbers of COVID-19 deaths. This results in a loss of information about differences in infection incidence between age groups <40yrs, especially between adults and children, given many children are still unvaccinated and therefore at higher risk of infection (41). As we assume the same infection risk for all individuals within each age group, the large lowest age group also means that we do not account for variation in infection risk for individuals <40yrs, despite the fact that infection risk varies with age in this group due to heterogeneity in contact patterns (31,42). The estimation issue created by low numbers of deaths in some countries could potentially be resolved by using age-stratified hospitalisation data in addition to, or instead of, death data. However, while this could provide more accurate estimates within each country, such data is not publicly available for all countries and differences in admission criteria between countries would limit comparability.
We assume that immunity acquired through infection provides approximately the same protection against infection, hospitalisation and death as two doses of a viral vector vaccine or mRNA vaccine. This is based on findings of similar levels of protection against symptomatic infection with the Delta variant from prior natural infection and two doses of the AstraZeneca/Pfizer vaccines in a large infection study in the UK (32), and estimates from some studies suggesting higher protection against hospitalisation and death from vaccination than prior infection (at least in individuals aged ≥65) (43) and estimates from others the opposite (44,45). However, some studies have observed higher rates of reinfection among previously infected individuals than vaccinees (46–48), suggesting that we may be underestimating the potential remaining burden among previously infected individuals. On the other hand, we do not account for stronger protection against reinfection among vaccinees who have been previously infected (44,45), which would have the opposite effect on the remaining burden estimates.

**Code**

The code and data underlying this analysis are available online at [https://github.com/LloydChapman/covid_remaining_burden](https://github.com/LloydChapman/covid_remaining_burden). The potential remaining burden estimates can be found in the output folder.
Supplementary Table S1. Effectiveness of 1st and 2nd doses of different vaccines against different COVID-19 outcomes

| Description                                                                 | Symbol          | Value | Source(s) |
|-----------------------------------------------------------------------------|-----------------|-------|-----------|
| Type A vaccines (AstraZeneca, Janssen, Sputnik, Beijing CNBG)               |                 |       |           |
| “Other” and Alpha variants \( k = 1, 2 \)                                    |                 |       |           |
| **Dose 1**                                                                  |                 |       |           |
| Protection against infection                                               | \( e_{ia,1,k} \ \( k = 1, 2 \) \) | 0.70  | (49–51)  |
| Protection against disease given infection                                  | \( e_{da,1,k} \ \( k = 1, 2 \) \) | 0.00  | (50,52,53) |
| Protection against hospitalisation given disease                            | \( e_{ha,1,k} \ \( k = 1, 2 \) \) | 0.50  | (19,54,55) |
| Protection against death given disease                                      | \( e_{ma,1,k} \ \( k = 1, 2 \) \) | 0.50  | (19,56)  |
| **Dose 2**                                                                  |                 |       |           |
| Protection against infection                                               | \( e_{ia,2,k} \ \( k = 1, 2 \) \) | 0.75  | (39,49,50,52) |
| Protection against disease given infection                                  | \( e_{da,2,k} \ \( k = 1, 2 \) \) | 0.20  | (50,57)  |
| Protection against hospitalisation given disease                            | \( e_{ha,2,k} \ \( k = 1, 2 \) \) | 0.50  | (19,55)  |
| Protection against death given disease                                      | \( e_{ma,2,k} \ \( k = 1, 2 \) \) | 0.75  | (58)  |
| **Delta variant**                                                           |                 |       |           |
| **Dose 1**                                                                  |                 |       |           |
| Protection against infection                                               | \( e_{ia,1,3} \) | 0.43  | (53,55)  |
| Protection against disease given infection                                  | \( e_{da,1,3} \) | 0.09  | (19,53,55,59,60) |
| Protection against hospitalisation given disease | $e_{ha,1,3}$ | 0.67 | (19,60,61) |
| Protection against death given disease | $e_{ma,1,3}$ | 0.67 | (19) |

**Dose 2**

| Protection against infection | $e_{i,a,2,3}$ | 0.63 | (53,55) |
| Protection against disease given infection | $e_{d,a,2,3}$ | 0.05 | (19,53,55,59,60) |
| Protection against hospitalisation given disease | $e_{ha,2,3}$ | 0.86 | (19,60,61) |
| Protection against death given disease | $e_{ma,2,3}$ | 0.86 | (19) |

**Type B vaccines (Pfizer, Moderna)**

**“Other” and Alpha variants**

**Dose 1**

| Protection against infection | $e_{ih,1,k}$ ($k = 1, 2$) | 0.70 | (49–51,53,62) |
| Protection against disease given infection | $e_{dh,1,k}$ ($k = 1, 2$) | 0.00 | (50,52,53) |
| Protection against hospitalisation given disease | $e_{ha,1,k}$ ($k = 1, 2$) | 0.5 | (19,52,54,55,63,64) |
| Protection against death given disease | $e_{ma,1,k}$ ($k = 1, 2$) | 0.5 | (19,56,64) |

**Dose 2**

| Protection against infection | $e_{ih,2,k}$ ($k = 1, 2$) | 0.85 | (39,49,50,53,62,65) |
| Protection against disease given infection | $e_{dh,2,k}$ ($k = 1, 2$) | 0.33 | (19,50,52,53,65) |
| Protection against hospitalisation given disease | $e_{h,b,2k}$ ($k = 1, 2$) | 0.5 | (19,55,64,65) |
| Protection against death given disease | $e_{m,b,2k}$ ($k = 1, 2$) | 0.5 | (19,56,64,65) |

**Delta variant**

### Dose 1

| Protection against infection | $e_{i,b1,3}$ | 0.62 | (53,55) |
| Protection against disease given infection | $e_{d,b1,3}$ | 0 | (19,53,55,59,60) |
| Protection against hospitalisation given disease | $e_{h,b,1,3}$ | 0.79 | (19,60,61) |
| Protection against death given disease | $e_{m,b,1,3}$ | 0.79 | (19) |

### Dose 2

| Protection against infection | $e_{i,b2,3}$ | 0.8 | (53,55) |
| Protection against disease given infection | $e_{d,b2,3}$ | 0.05 | (19,53,55,59,60) |
| Protection against hospitalisation given disease | $e_{h,b,2,3}$ | 0.84 | (19,60,61) |
| Protection against death given disease | $e_{m,b,2,3}$ | 0.84 | (19) |
Supplementary Table S2. Vaccination status reported by participants of Robert Koch Institute (RKI) COVIMO study on vaccine uptake in Germany, 15th Sep - 18th Oct 2021 (n=3309) (from (8))

| Age group (yrs) | Percentage vaccinated at least once* (%) |
|----------------|----------------------------------------|
| 18-29          | 88.2                                   |
| 30-39          | 81.9                                   |
| 40-49          | 87.8                                   |
| 50-59          | 88.9                                   |
| 60-69          | 93.5                                   |
| 70-79          | 95.5                                   |
| 80+            | 96.6                                   |

*These coverages are much higher than the official vaccination coverages for broader age groups (12-17, 18-59, 60+yrs) reported by RKI (7), likely due to selection bias in the survey participants, but can be used to calculate relative vaccination coverage within the broader age groups.

Supplementary Table S3. Distributions of durations of infection stages in difference equation model

| Waiting time                      | Distribution*  | Mean (days) | Reference |
|-----------------------------------|----------------|-------------|-----------|
| Latent period duration, $d_E$     | Gamma(2.5, 1)  | 2.5         | (18,66)   |
| Subclinical latent period duration, $d_L$ | Gamma(2.5, 1)  | 2.5         | (18)      |
| Preclinical infection duration, $d_P$ | Gamma(4, 0.625) | 2.5     | (18,66)   |
| Clinical infection duration, $d_C$ | Gamma(4, 0.625) | 2.5      | (18)      |
| Subclinical infection duration, $d_S$ | Gamma(4, 1.25) | 5          | (18)      |

*All Gamma distributions are discretised to be in time steps of 1 day, as the data and difference equation model are discrete with day time steps.
Supplementary Table S4. Estimates of numbers in different immune states and potential remaining burden of COVID-19 hospitalisations and deaths in 19 European countries as of 21st November 2021*

| Country   | Population (millions) | Vaccination coverage (%) | Unvaccinated & unexposed (millions) | Vaccinated & uninfected (millions) | Previously infected (millions) | Proportion unvaccinated & unexposed (%)** | Proportion vaccinated & uninfected (%)** | Proportion previously infected (%)** | Maximum remaining hospitalisations | Maximum remaining deaths | Maximum remaining hospitalisations/100,000 people | Maximum remaining deaths/100,000 people |
|-----------|-----------------------|---------------------------|--------------------------------------|-------------------------------------|---------------------------------|-----------------------------------------|----------------------------------------|-------------------------------------|-------------------------------|------------------|------------------------------------------------|-------------------------------|
| Austria   | 9.0                   | 65.1                      | 2.7 (2.5-2.8)                        | 5.3 (5.2-5.3)                       | 1.0 (0.8-1.2)                  | 30 (28-31)                             | 59 (57-59)                             | 11 (9-14)                          | 63000 (51000-770 00)               | 11000 (9300-1200 0)            | 700 (570-860)                                   | 120 (100-140)                |
| Belgium   | 11.6                  | 75.0                      | 2.2 (1.9-2.4)                        | 7.3 (7-7.4)                         | 2.0 (1.7-2.4)                  | 19 (17-21)                             | 63 (61-64)                             | 17 (15-21)                         | 74000 (57000-920 00)               | 16000 (14000-190 00)            | 640 (490-800)                                   | 140 (120-160)                |
| Czechia   | 10.7                  | 57.6                      | 3.0 (2.5-3.3)                        | 4.3 (4.1-4.5)                       | 3.3 (2.9-3.8)                  | 28 (23-30)                             | 40 (38-42)                             | 31 (27-35)                         | 79000 (63000-960 00)               | 14000 (12000-160 00)            | 740 (590-900)                                   | 130 (110-150)                |
| Denmark   | 5.8                   | 71.8                      | 1.5 (1.4-1.6)                        | 4.0 (3.4-4)                         | 0.3 (0.2-1.9)                  | 26 (24-27)                             | 69 (58-69)                             | 5 (4-32)                           | 20000 (16000-280 00)               | 2900 (2600-3900)               | 350 (280-480)                                   | 51 (44-68)                   |
| England   | 56.0                  | 73.5                      | 10.2 (9.1-10.9)                      | 30.3 (29.2-31.2)                    | 15.1 (13.6-16.8)              | 18 (16-20)                             | 54 (52-56)                             | 27 (24-30)                         | 180000 (140000-22 0000)           | 33000 (28000-380 00)            | 320 (250-390)                                   | 58 (50-67)                   |
| Finland   | 5.5                   | 76.0                      | 1.2 (1.1-1.2)                        | 4.0 (3.9-4)                         | 0.4 (0.3-0.6)                  | 21 (19-22)                             | 72 (70-73)                             | 7 (5-10)                           | 31000 (24000-450 000)             | 5900 (4300-8900)               | 560 (430-820)                                   | 110 (78-160)                 |
| France    | 65.3                  | 78.4                      | 11.5 (10.8-11.9)                     | 43.0 (41.9-43.6)                    | 10.6 (9.7-11.8)               | 18 (17-18)                             | 66 (64-67)                             | 16 (15-18)                         | 360000 (280000-46 0000)           | 80000 (68000-940 00)            | 560 (430-700)                                   | 120 (100-140)                |
| Germany   | 83.8                  | 64.7                      | 25.5 (24.6-26)                       | 48.7 (48.3-49.1)                    | 9.4 (8.6-10.4)                 | 30 (29-31)                             | 58 (58-59)                             | 11 (10-12)                         | 820000 (650000-10 00000)          | 170000 (150000-19 00000)        | 970 (770-1200)                                  | 200 (170-220)                |
| Greece    | 10.4                  | 62.8                      | 2.7 (2.3-2.9)                        | 5.1 (5-5.3)                         | 2.4 (2.1-2.8)                  | 26 (22-28)                             | 49 (47-51)                             | 23 (20-26)                         | 120000 (89000-160)                | 30000 (25000-360)              | 1200 (850-1500)                                  | 290 (240-350)                |
| Country    | Delta | 76.3 | 95% CrI | Delta | 75.0 | 95% CrI | 12.0 | 95% CrI | 20.0 | 95% CrI | 14.0 | 95% CrI |
|------------|-------|------|---------|-------|------|---------|------|---------|------|---------|------|---------|
| Hungary    | 9.7   | 60.9 | 0.4     | 0.1-0.8 | 1.9   | 1.3-2.3 | 7.0   | 6.3-7.8 | 5.0   | 1-9     | 19   | 13-23   |
| Italy      | 60.5  | 76.3 | 11.5    | 10.4-11.9 | 38.3  | 37.6-38.9 | 10.4  | 9.5-11.6 | 19   | 17-20   | 63   | 62-64   |
| Netherland | 17.1  | 71.6 | 4.4     | 4.2-4.5 | 11.4  | 11.3-11.5 | 1.2   | 1-1.5    | 26   | 25-26   | 67   | 66-67   |
| Norway     | 5.4   | 77.5 | 1.2     | 1.1-1.2 | 4.1   | 4-4.1   | 0.1   | 0.1-0.3  | 22   | 21-22   | 75   | 74-76   |
| Portugal   | 10.2  | 87.6 | 1.1     | 0.9-1.1 | 7.6   | 7.3-7.7 | 1.5   | 1.3-1.9  | 10   | 9-11    | 74   | 71-76   |
| Romania    | 19.2  | 33.5 | 2.0     | 1.5-3.2 | 2.3   | 1.6-2.9 | 14.3  | 12.8-15.5 | 11   | 8-16    | 74   | 66-80   |
| Slovakia   | 5.5   | 44.3 | 1.3     | 0.9-1.6 | 1.4   | 1.3-1.5 | 2.6   | 2.3-3.2  | 25   | 16-29   | 25   | 23-27   |
| Slovenia   | 2.1   | 56.6 | 0.8     | 0.7-0.8 | 1.0   | 1.0-1.0 | 0.3   | 0.2-0.4  | 37   | 33-39   | 48   | 46-49   |
| Spain      | 46.8  | 81.3 | 6.7     | 6.1-7.1 | 31.1  | 30.3-31.6 | 8.8   | 8-9.9    | 14   | 13-15   | 66   | 65-68   |
| Sweden     | 10.1  | 69.1 | 2.4     | 2.1-2.6 | 6.0   | 5.8-6.1 | 1.7   | 1.4-2.1  | 24   | 21-25   | 59   | 57-61   |

*Numbers in parentheses are 95% credible intervals. **Proportions sum to slightly less than 100% as currently infected individuals are not included.
Supplementary Figure S1. (A) Vaccine coverage and (B) IFR over time (calculated using Equation (3)) by age group and country since 1st December 2020. Shaded bands in (B) show 95% credible intervals based on a truncated normal approximation to posterior distribution of IFR in (13).

Supplementary Figure S2. Age-stratified death time series from the COVerAGE database (1,2) used to infer age-stratified infection time series in Figure 2A in the main text.
Supplementary Figure S3. Estimated cumulative proportion infected or vaccinated (solid lines) and modelled seroprevalence estimates (dashed lines) for England by age group. Shaded regions show 95% credible intervals. Seroprevalence estimates from the UK Office of National Statistics (ONS) (67). Seroprevalence estimates for 0-39-year-olds are not available as the serological testing in the ONS Coronavirus Infection Survey only covers adults aged ≥16yrs.

Supplementary Figure S4. (A) Maximum remaining COVID-19 deaths by age group and country (assuming no waning of immunity or emergence of immune escape variants), and (B) relationship between overall remaining deaths per 100,000 population and proportion who have received at least one vaccine dose across countries. Note upper limit of horizontal axis in (A) has been truncated to ensure differences between countries remain visible and vertical axis in (B) is on log scale. Supplementary Figure S6B shows plot (A) without truncation of the horizontal axis.
Supplementary Figure S5. Relationship between maximum remaining burden of (A) hospitalisations and (B) deaths and proportion of the population 60 or more years of age across countries. Note vertical axes are on the log scale.

Supplementary Figure S6. Estimated maximum remaining (A) hospitalisations and (B) deaths per 100,000 population by country, age group and immune status.
Supplementary Figure S7. Estimated proportions of different variants in each country over time from multinomial regression model fitted to data on numbers of sequences of different variants. Aggregated sequence data from ECDC (EU countries) (11) and COVID-19 Genomics UK consortium (England) (12).
Supplementary Figure S8. Inferred infection time series (solid lines) and reported cases (dashed lines) by country (columns) and age group (rows). Reported cases by age group obtained from ECDC database (68) and UK government’s COVID-19 dashboard (6), and observed and inferred counts re-aggregated into matching age groups.
References

1. Riffe T, Acosta E, the COVerAGE-DB team, Acosta EJ, Manuel Aburto D, Alburez-Gutierrez A, et al. Data Resource Profile: COVerAGE-DB: a global demographic database of COVID-19 cases and deaths. Int J Epidemiol. 2021 May 15;50(2):390–390f.

2. Riffe T, Acosta E, Schöley J, Donzowa J, Kniffka MS. COVerAGE-DB: A database of COVID-19 cases and deaths by age. 2020 Apr 9 [cited 2021 Oct 21]; Available from: https://osf.io/mpwjq/

3. Demographics of COVID-19 Deaths [Internet]. [cited 2021 Oct 21]. Available from: https://dc-covid.site.ined.fr/en/

4. Palmer J, Sherratt K, Martin-Nielsen R, Bevan J, Gibbs H, Cmmid Group, et al. covidregionaldata: Subnational data for COVID-19 epidemiology. J Open Source Softw. 2021 Jul 5;6(63):3290.

5. Data on COVID-19 vaccination in the EU/EEA [Internet]. 2021 [cited 2021 Oct 21]. Available from: https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea

6. UK Coronavirus Dashboard [Internet]. [cited 2021 Nov 4]. Available from: https://coronavirus.data.gov.uk/details/download

7. Robert Koch-Institut. COVID-19-Impfungen in Deutschland [Internet]. [cited 2021 Nov 24]. Available from: https://github.com/robert-koch-institut/COVID-19-Impfungen_in_Deutschland

8. Robert Koch-Institute. COVID-19 Vaccination Rate Monitoring in Germany - Report 8 [Internet]. [cited 2021 Nov 24]. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/COVIMO_Reports/covimo_studie_bericht_8.pdf?__blob=publicationFile

9. GISAID - Initiative [Internet]. [cited 2021 Oct 21]. Available from: https://www.gisaid.org/

10. The European Surveillance System (TESSy) [Internet]. [cited 2021 Oct 21]. Available from: https://www.ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy

11. Data on SARS-CoV-2 variants in the EU/EEA [Internet]. 2021 [cited 2021 Oct 22]. Available from: https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covid-19-eueea

12. COVID-19 Genomic Surveillance – Wellcome Sanger Institute [Internet]. [cited 2021 Oct 21]. Available from: https://covid19.sanger.ac.uk/downloads

13. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021 Feb;590(7844):140–5.

14. World Population Prospects - Population Division - United Nations [Internet]. [cited 2021 Oct 21]. Available from: https://population.un.org/wpp/Download/Standard/Interpolated/
15. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020 Aug;584(7820):257–61.

16. Unwin HJT, Mishra S, Bradley VC, Gandy A, Mellan TA, Coupland H, et al. State-level tracking of COVID-19 in the United States. Nat Commun. 2020 Dec 3;11(1):1–9.

17. Louca S. SARS-CoV-2 infections in 165 countries over time. Int J Infect Dis. 2021 Oct;111:336–46.

18. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science [Internet]. 2021 Apr 9;372(6538). Available from: http://dx.doi.org/10.1126/science.abg3055

19. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv. 2021 Oct 6;2021.09.15.21263583.

20. Pereira E, Giji S, Gabb V. Coronavirus (COVID-19) Infection Survey technical article: analysis of reinfections of COVID-19 - Office for National Statistics [Internet]. Office for National Statistics; 2021 [cited 2021 Dec 9]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticleanalysisofreinfectionsofcovid19/june2021

21. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993 Aug;22(4):742–6.

22. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill [Internet]. 2021 Jun;26(24). Available from: http://dx.doi.org/10.2807/1560-7917.ES.2021.26.24.2100509

23. Obermeyer F, Schaffner SF, Jankowiak M, Barkas N, Pyle JD, Park DJ, et al. Analysis of 2.1 million SARS-CoV-2 genomes identifies mutations associated with transmissibility. medRxiv. 2021 Sep 13;2021.09.07.21263228.

24. Miller AC, Hannah L, Futoma J, Foti NJ, Fox EB, D’Amour A, et al. Statistical deconvolution for inference of infection time series. medRxiv. 2020 Oct 20;2020.10.16.20212753.

25. Miller A, Hannah L, Foti N, Futoma J, Apple Inc. incidental R package version 0.1. 2020 Sep 16 [cited 2021 Oct 20]; Available from: https://CRAN.R-project.org/package=incidental

26. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020 Dec;35(12):1123–38.

27. Gostic KM, McGough L, Baskerville EB, Abbott S, Joshi K, Tedijanto C, et al. Practical considerations for measuring the effective reproductive number, Rt. PLoS Comput Biol. 2020 Dec;16(12):e1008409.

28. Comas-Herrera A, Zalakain J, Lemmon E, Henderson D, Litwin C, Hsu AT, et al. Mortality
associated with COVID-19 in care homes: international evidence [Internet]. International Long-Term Care Policy Network; 2021 Feb [cited 2021 Oct 21]. Available from: https://ltccovid.org/wp-content/uploads/2021/02/LTC_COVID_19_international_report_January-1-February-1-1.pdf

29. Brazeau NF, Verity R, Jenks SJ, Fu H, Whittaker C, Winskill P, et al. Report 34: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence [Internet]. Available from: https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-10-29-COVID19-Report-34.pdf

30. Hardy OJ, Dubourg D, Bourguignon M, Dellicour S, Eggerickx T, Gilbert M, et al. A world apart: levels and factors of excess mortality due to COVID-19 in care homes. The case of Wallonia - Belgium [Internet]. Available from: http://dx.doi.org/10.1101/2020.08.29.20183210

31. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 working group, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020 Aug;26(8):1205–11.

32. Bubb E. Coronavirus (COVID-19) Infection Survey Technical Article: Impact of vaccination on testing positive in the UK - Office for National Statistics [Internet]. Office for National Statistics; 2021 [cited 2021 Dec 9]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticleimpactofvaccinationonetestingpositiveintheuk/october2021

33. Salje H, Tran Kiern C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020 Jul 10;369(6500):208–11.

34. Demographics of COVID-19 Deaths [Internet]. [cited 2021 Dec 9]. Available from: https://dc-covid.site.ined.fr/en/

35. The Economist. Tracking covid-19 excess deaths across countries. The Economist [Internet]. 2021 Oct 20 [cited 2021 Dec 9]; Available from: https://www.economist.com/graphic-detail/coronavirus-excess-deaths-tracker

36. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 May;593(7858):270–4.

37. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021 Mar 9;372:n579.

38. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamy MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis [Internet]. 2021 Aug 27; Available from: http://dx.doi.org/10.1016/S1473-3099(21)00475-8

39. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021 Jun 26;397(10293):2461–2.
40. Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada [Internet]. bioRxiv. medRxiv; 2021. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.05.21260050

41. Willis KSA. Coronavirus (COVID-19) Infection Survey, UK - Office for National Statistics [Internet]. Office for National Statistics; 2021 [cited 2021 Dec 9]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/12november2021

42. Jarvis CI, Van Zandvoort K, Gimma A, Prem K, CMMID COVID-19 working group, Klepac P, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. BMC Med. 2020 May 7;18(1):124.

43. Young-Xu Y, Smith J, Korves C. SARS-Cov-2 Infection versus Vaccine-Induced Immunity among Veterans. medRxiv. 2021 Sep 29;2021.09.27.21264194.

44. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv. 2021 Aug 25;2021.08.24.21262415.

45. Do I need a COVID vaccine if I’ve had COVID? [Internet]. [cited 2021 Dec 9]. Available from: https://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covid

46. Bozio CH. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Dec 9];70. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e1.htm

47. Cavanaugh AM. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Dec 9];70. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm

48. What’s the difference between natural and vaccine immunity against COVID-19? [Internet]. [cited 2021 Dec 9]. Available from: https://covid.joinzoe.com/post/covid-vaccine-natural-immunity-difference

49. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study). medRxiv. 2021 Mar 26;2021.03.26.21254391.

50. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021 Aug;27(8):1370–8.

51. Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett SJ, et al. Assessing COVID-19 Vaccine Uptake and Effectiveness Through the North West London Vaccination Program: Retrospective Cohort Study. JMIR Public Health and Surveillance. 2021 Sep 17;7(9):e30010.
52. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ [Internet]. 2021 May 13 [cited 2021 Oct 21];373. Available from: https://www.bmj.com/content/373/bmj.n1088.abstract

53. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK [Internet]. Nature Medicine. 2021. Available from: http://dx.doi.org/10.1038/s41591-021-01548-7

54. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021 May 1;397(10285):1646–57.

55. Ismail SA, Vilaplana TG, Elgohari S, Stowe J, Tessier E, Andrews N, et al. Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: an observational study using surveillance data. [cited 2021 Oct 22]; Available from: https://khub.net/documents/135939561/430986542/Effectiveness+of+BNT162b2+mRNA+and+ChAdOx1+adenovirus+vector+COVID-19+vaccines+on+risk+of+hospitalisation+among+older+adults+in+England.pdf/9e18c525-dde6-5ee4-1537-91427798686b

56. Bernal JL, Andrews N, Gower C, Stowe J, Tessier E, Simmons R, et al. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. medRxiv. 2021 May 18;2021.05.14.21257218.

57. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.

58. Public Health England. COVID-19 vaccine surveillance report - Week 26 [Internet]. [cited 2021 Oct 22]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/998411/Vaccine_surveillance_report_-_week_26.pdf

59. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 Aug 12;385(7):585–94.

60. Public Health England. COVID-19 vaccine surveillance report - Week 36 [Internet]. [cited 2021 Oct 22]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1016465/Vaccine_surveillance_report_-_week_36.pdf

61. Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1617.2) variant [Internet]. [cited 2021 Oct 22]. Available from: https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf
62. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021 May 8;397(10286):1725–35.

63. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis [Internet]. 2021 Jun 23; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309921003303

64. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Apr 15;384(15):1412–23.

65. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819–29.

66. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020 May 5;172(9):577–82.

67. Davies RYA. Coronavirus (COVID-19) Infection Survey, antibody and vaccination data, UK [Internet]. Office for National Statistics; 2021 [cited 2021 Dec 9]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19antibodydatafortheuk

68. Data on the 14-day age-specific notification rate of new COVID-19 cases [Internet]. 2021 [cited 2021 Oct 21]. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-data-14-day-age-notification-rate-new-cases